Oncimmune has released results for the 12m period to May-22, ahead of its changed year and to August. These results reflect a period of investment into the commercial team for ImmunoINSIGHTS and increased penetration into the Top 15 global pharma customers, where a number of MSAs have been signed. These are expected to translate into faster contract wins and management reports a current weighted value pipeline of £11.0m across the business, providing increased revenue visibility. Cost savings in ....
21 Sep 2022
12m to May-22 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
12m to May-22 results
Oncimmune Holdings Plc (ONC:LON) | 27.6 -0.4 (-5.2%) | Mkt Cap: 20.5m
- Published:
21 Sep 2022 -
Author:
Chris Glasper -
Pages:
3
Oncimmune has released results for the 12m period to May-22, ahead of its changed year and to August. These results reflect a period of investment into the commercial team for ImmunoINSIGHTS and increased penetration into the Top 15 global pharma customers, where a number of MSAs have been signed. These are expected to translate into faster contract wins and management reports a current weighted value pipeline of £11.0m across the business, providing increased revenue visibility. Cost savings in ....